Brief: Innovation Pharmaceuticals provides development update on Brilacidin
24/10/2017 12:30
Oct 24 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK
* Innovation Pharmaceuticals provides development update on
Brilacidin for inflammatory bowel disease
Source text for Eikon: ID:nGNXOGGFSa
Further company coverage: IPIX.PK
((Bangalore.newsroom@thomsonreuters.com; ;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review